var data={"title":"Domperidone (United States: Available via FDA investigational drug [IND] protocol only): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Domperidone (United States: Available via FDA investigational drug [IND] protocol only): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6067?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">see &quot;Domperidone (United States: Available via FDA investigational drug [IND] protocol only): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162491\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Domperidone;</li>\n      <li>Dom-Domperidone;</li>\n      <li>Jamp-Domperidone;</li>\n      <li>Mar-Domperidone;</li>\n      <li>Mylan-Domperidone;</li>\n      <li>PMS-Domperidone;</li>\n      <li>RAN-Domperidone;</li>\n      <li>ratio-Domperidone;</li>\n      <li>Teva-Domperidone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162531\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Dopamine Antagonist;</li>\n      <li>\n        Gastrointestinal Agent, Prokinetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162495\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>GI motility disorders (diabetic gastroparesis, gastritis), Nausea/vomiting associated with dopamine-agonist anti-Parkinson agents:</b>  Oral: 10 mg 3 times daily (maximum: 30 mg/day). Use the lowest effective dose for the shortest duration necessary. For gastroparesis, the American College of Gastroenterology recommends initiating at 10 mg 3 times daily (Camilleri 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062960\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162496\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however, depending on severity of impairment, frequency should be reduced to 1 to 2 times daily and dosage reduction considered with repeated administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10869539\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution (undergoes hepatic metabolism).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Moderate or severe impairment: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950036\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral: 10 mg [domperidone maleate 12.72 mg]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11233709\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841022\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Domperidone is available via an Investigational New Drug Application (IND) in the United States for severe GI disorders refractory to standard therapy. For more information on the requirements for the IND, contact the Food and Drug Administration (FDA) at 301-796-3400.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162472\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: In GI motility disorders, administer 15 to 30 minutes prior to meals and at bedtime if needed. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162471\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>GI motility disorders:</b> Symptomatic management of upper GI motility disorders associated with chronic and subacute gastritis and diabetic gastroparesis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nausea/vomiting associated with dopamine-agonist anti-Parkinson agents:</b> Prevention of GI symptoms (eg, nausea, vomiting) associated with use of dopamine-agonist anti-Parkinson agents</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9770161\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Domperidone may be confused with iloperidone, paliperidone</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162461\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (&le;1%), migraine (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal cramps, acid regurgitation, change in appetite, conjunctivitis, constipation, diarrhea, dizziness, dysuria, edema, extrapyramidal reaction (rare), galactorrhea, gynecomastia, heartburn, hot flash, increased serum ALT, increased serum AST, increased serum cholesterol, increased serum prolactin, increased thirst, insomnia, irritability, leg cramps, lethargy, mastalgia, menstrual disease, nausea, nervousness, palpitations, pruritus, skin rash, stomatitis, torsades de pointes, urinary frequency, urticaria, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162475\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to domperidone or any component of the formulation; prolactin-releasing pituitary tumor (prolactinoma); known existing prolongation of cardiac conduction intervals, particularly QT; significant electrolyte disturbances; underlying cardiac disease (eg, heart failure); moderate or severe hepatic impairment; patients with GI hemorrhage, mechanical obstruction, or perforation; concomitant use with potent CYP3A4 inhibitors such as azole antifungals (eg, ketoconazole), macrolides (eg, erythromycin), protease inhibitors, or  nefazodone; concomitant use with QT-prolonging drugs</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162459\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered cardiac conduction: <b>[Canadian Boxed Warning]: Domperidone may be associated with an increased risk of serious ventricular arrhythmias or sudden cardiac death, particularly with doses &gt;30 mg or when used in patients &gt;60 years of age. Use the lowest possible dose for the shortest duration necessary.</b> Do not exceed 30 mg/day. Avoid use of domperidone for the following: concomitant use of drugs which prolong the QTc interval and with potent CYP3A4 inhibitors which may increase domperidone exposure, existing prolongation of cardiac conduction intervals (particularly QT), significant electrolyte disturbances or underlying cardiac diseases (eg, heart failure). QTc prolongation, life-threatening tachyarrhythmias (eg, torsade de pointes), and cardiac arrest have been reported after use; these adverse effects may be precipitated in patients with preexisting prolonged cardiac conduction or other underlying cardiac disease, hypokalemia, or receiving other QTc-prolonging agents. The American College of Gastroenterology guidelines recommend baseline and follow-up ECGs and avoiding use if corrected QT is &gt;450 msec in male patients or &gt;470 msec in female patients (Arnold 2013; Camilleri 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elevated prolactin levels: May increase prolactin levels (dose-dependent response); may be asymptomatic (clinical consequence of chronically-elevated prolactin is unknown) or may present symptomatically as galactorrhea, gynecomastia, amenorrhea, or impotence (reversible upon decreasing dose or discontinuing drug). Use is contraindicated in patients with prolactinomas.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Breast cancer: Use caution when administering to patients with a personal or family history of breast cancer; evidence regarding an association between chronic use of dopamine-receptor antagonists and breast cancer is limited and nonconclusive.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Undergoes extensive hepatic metabolism; use is contraindicated in patients with moderate to severe hepatic impairment; use with caution in mild impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; dosage and/or frequency of administration may need adjusted with repeated use and/or long-term therapy. Monitor renal function regularly, particularly with long-term therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Breast milk production stimulant: In 2004, the Food and Drug Administration (FDA) issued a warning recommending that domperidone not be used off-label to increase milk production in breast-feeding women due to safety concerns. Several cases of cardiac arrhythmia, cardiac arrest, and sudden death have been reported in patients receiving intravenous domperidone. The risk of similar adverse events in breast-feeding women is unknown. Domperidone is not available for any use in the United States (except via severe GI disorder IND) and does not have approval for this indication in other countries.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162526\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2B6 (minor), CYP2C8 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162463\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8777&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Domperidone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Domperidone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Domperidone. Monoamine Oxidase Inhibitors may diminish the therapeutic effect of Domperidone. Domperidone may diminish the therapeutic effect of Monoamine Oxidase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46106881\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Domperidone serum concentrations may be increased when taken with grapefruit juice. Management: Avoid concurrent use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162478\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal studies have not shown drug-related teratogenic or primary embryotoxic effects on animal fetuses; however, studies have not been done in humans.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162479\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Domperidone is excreted in low concentrations in breast milk</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162467\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function; ECG (baseline and then periodically during therapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162458\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Domperidone has peripheral dopamine receptor blocking properties and does not readily cross the blood-brain barrier. It increases esophageal peristalsis and increases lower esophageal sphincter pressure, increases gastric motility and peristalsis, and enhances gastroduodenal coordination, therefore, facilitating gastric emptying and decreasing small bowel transit time.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162474\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 93% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP3A4, N-dealkylation and hydroxylation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 7 hours (increases to ~21 hours in severe renal impairment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak serum concentration: 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (66%); urine (31%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162481\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agilam (VE);</li>\n      <li>Almedon (PK);</li>\n      <li>Apildon (HK);</li>\n      <li>Bropasmo (PY);</li>\n      <li>Cilroton (GR);</li>\n      <li>Costi (TW);</li>\n      <li>Costil (ID);</li>\n      <li>Dany (TH);</li>\n      <li>Dispel (PH);</li>\n      <li>Domerdon (TH);</li>\n      <li>Domerid (IE, MT);</li>\n      <li>Dometa (ID);</li>\n      <li>Domp (BD, TH);</li>\n      <li>Domp-M (TH);</li>\n      <li>Dompe (TW);</li>\n      <li>Domper (MY, PH, TW);</li>\n      <li>Domperid (CN);</li>\n      <li>Domperine (KR);</li>\n      <li>Dompil (VN);</li>\n      <li>Dompy (AE, QA);</li>\n      <li>Domstal (IN, ZW);</li>\n      <li>Don-A (PH);</li>\n      <li>Dosin (CL);</li>\n      <li>Emelium (LK);</li>\n      <li>Gasdol (CL);</li>\n      <li>Gasidone (PH);</li>\n      <li>Gastroflux (GT);</li>\n      <li>Gerdilium (ID);</li>\n      <li>GI Norm (PH);</li>\n      <li>Hamidon (KR);</li>\n      <li>Harmetone (CO);</li>\n      <li>Idon (PE, PY);</li>\n      <li>Mocydone M (TH);</li>\n      <li>Mododom (AE, QA);</li>\n      <li>Modomed (TH);</li>\n      <li>Mogasinte (PT);</li>\n      <li>Motidone (MY);</li>\n      <li>Motigut (MY);</li>\n      <li>Motilat (JO, LB);</li>\n      <li>Motilium (AE, AR, AT, AU, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CN, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FR, GB, GT, GY, HK, HN, HU, ID, IE, IL, IT, JM, JO, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NZ, PA, PE, PH, PK, PR, PT, PY, QA, RO, RU, SG, SR, SV, TR, TT, TW, UY, VN, ZA, ZW);</li>\n      <li>Motilium [tabs.] (PL);</li>\n      <li>Motinorm (IN, PH);</li>\n      <li>Motylium (UA);</li>\n      <li>Mutilium (SA);</li>\n      <li>Nausylium (UA);</li>\n      <li>Nauzelin (ES, JP);</li>\n      <li>Netaf (PE);</li>\n      <li>Nidolium (TW);</li>\n      <li>Ninlium (TH);</li>\n      <li>Nordonil (PT);</li>\n      <li>Oroperidys (FR);</li>\n      <li>Pepridon (PH);</li>\n      <li>Peptomet (CY);</li>\n      <li>Peridon (IT, JO);</li>\n      <li>Peridone (LK);</li>\n      <li>Peridys (FR);</li>\n      <li>Perydon (UA);</li>\n      <li>Prokinin (QA);</li>\n      <li>Rabugen (MY);</li>\n      <li>Rabugen-M (HK, MY);</li>\n      <li>Remotil (PT);</li>\n      <li>Seronex (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Siligaz (CL);</li>\n      <li>Smood (MY);</li>\n      <li>Stopvom (IN);</li>\n      <li>Tametil (HR);</li>\n      <li>Tilidon (ID);</li>\n      <li>Vave (BD);</li>\n      <li>Vemetis-10 (HK);</li>\n      <li>Vometa (ID, PH);</li>\n      <li>Vometa FT (LK, MY);</li>\n      <li>Vomitil (PK);</li>\n      <li>Vomitil-M (TH);</li>\n      <li>Weitul (TW);</li>\n      <li>Xepadon (BD);</li>\n      <li>Yaridon (ID);</li>\n      <li>Zidon-DT (IN);</li>\n      <li>Zilium (BE);</li>\n      <li>Zydom (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Apo-Domperidone (domperidone) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24005360\"></a>Arnold G, Beaves M. Update on clinical guidelines for the management of gastroparesis. <i>Am J Gastroenterol</i>. 2013;108(9):1538-1539.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/24005360/pubmed\" target=\"_blank\" id=\"24005360\">24005360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Camilleri M, Parkman HP, Shafi MA, et al, &ldquo;Clinical Guideline: Management of Gastroparesis,&rdquo; <i>Am J Gastroenterol</i>, 2013, 108(1):18&ndash;37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/23147521/pubmed\" target=\"_blank\" id=\"23147521\">23147521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    da Silva OP, Knoppert DC, Angelini MM, et al, &ldquo;Effect of Domperidone on Milk Production in Mothers of Premature Newborns: A Randomized, Double-Blind, Placebo-Controlled Trial,&rdquo; <i>CMAJ</i>, 2001, 164(1):17-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/11202662/pubmed\" target=\"_blank\" id=\"11202662\">11202662</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drolet B, Rousseau G, Daleau P, et al, &ldquo;Domperidone Should Not be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders,&rdquo; <i>Circulation</i>, 2000, 102(16):1883-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/11034933/pubmed\" target=\"_blank\" id=\"11034933\">11034933</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dumitrascu DL and Weinbeck M, &ldquo;Domperidone Versus Metoclopramide in the Treatment of Diabetic Gastroparesis,&rdquo; <i>Am J Gastroenterol</i>, 2000, 95(1):316-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-drug-information/abstract-text/10638616/pubmed\" target=\"_blank\" id=\"10638616\">10638616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;FDA Warns Against Women Using Unapproved Drug, Domperidone, to Increase Milk Production.&rdquo; Available at <a href=\"http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154914.htm\" target=\"_blank\">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154914.htm</a></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8777 Version 134.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F162491\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F162531\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F162495\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062960\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F162496\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F10869539\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950036\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11233709\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F13841022\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F162472\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F162471\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9770161\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F162461\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F162475\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F162459\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F162526\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F162463\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F46106881\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F162478\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F162479\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F162467\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F162458\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F162474\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F162481\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8777|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=domperidone-united-states-available-via-fda-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">Domperidone (United States: Available via FDA investigational drug [IND] protocol only): Patient drug information</a></li></ul></div></div>","javascript":null}